

Think | Test | Treat
Because monitoring and testing matters
WHAT IS THINK
TEST TREAT?
The THINK TEST TREAT programme was initiated by Incyte to raise awareness of the importance of regular and sensitive BCR-ABL1 monitoring and guidance-compliant mutation testing in patients with Ph+ leukaemias
Read moreCML
Why is it important to think about sensitive BCR-ABL1 monitoring and mutation testing when treating patients with CML?
Read morePh+ ALL
Why is it important to monitor minimal residual disease and test for mutations when treating patients with Ph+ ALL?
Read more